Weber M, Hausen M, Arnold R, Nef H, Moellman H, Berkowitsch A, Elsaesser A, Brandt R, Mitrovic V, Hamm C
Kerckhoff Heart Center, Department of Cardiology, Bad Nauheim, Germany.
Heart. 2006 Nov;92(11):1639-44. doi: 10.1136/hrt.2005.085506. Epub 2006 Jun 1.
To evaluate the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with aortic stenosis being treated conservatively or undergoing aortic valve replacement (AVR).
159 patients were followed up for a median of 902 days. 102 patients underwent AVR and 57 were treated conservatively. NT-proBNP at baseline was raised in association with the degree of severity and of functional status.
During follow up 21 patients (13%) died of cardiac causes or required rehospitalisation for decompensated heart failure. NT-proBNP at baseline was higher in patients with an adverse outcome than in event-free survivors (median 623 (interquartile range 204-1854) pg/ml v 1054 (687-2960) pg/ml, p = 0.028). This difference was even more obvious in conservatively treated patients (331 (129-881) pg/ml v 1102 (796-2960) pg/ml, p = 0.002). Baseline NT-proBNP independently predicted an adverse outcome in the entire study group and in particular in conservatively treated patients (area under the curve (AUC) = 0.65, p = 0.028 and AUC = 0.82, p = 0.002, respectively) but not in patients undergoing AVR (AUC = 0.544). At a cut-off value of 640 pg/ml, baseline NT-proBNP was discriminative for an adverse outcome.
NT-proBNP concentration is related to severity of aortic stenosis and provides independent prognostic information for an adverse outcome. However, this predictive value is limited to conservatively treated patients. Thus, the data suggest that assessing NT-proBNP may have incremental value for selecting the optimal timing of valve replacement.
评估N末端B型利钠肽原(NT-proBNP)对接受保守治疗或主动脉瓣置换术(AVR)的主动脉瓣狭窄患者的预后价值。
对159例患者进行了中位时间为902天的随访。102例患者接受了AVR,57例接受了保守治疗。基线时NT-proBNP水平升高与疾病严重程度和功能状态相关。
随访期间,21例患者(13%)死于心脏原因或因失代偿性心力衰竭再次住院。不良结局患者的基线NT-proBNP水平高于无事件存活者(中位数623(四分位间距204 - 1854)pg/ml对1054(687 - 2960)pg/ml,p = 0.028)。这种差异在保守治疗的患者中更为明显(331(129 - 881)pg/ml对1102(796 - 2960)pg/ml,p = 0.002)。基线NT-proBNP在整个研究组中,尤其是在保守治疗的患者中独立预测不良结局(曲线下面积(AUC)= 0.65,p = 0.028和AUC = 0.82,p = 0.002),但在接受AVR的患者中无此作用(AUC = 0.544)。基线NT-proBNP的截断值为640 pg/ml时,对不良结局具有鉴别意义。
NT-proBNP浓度与主动脉瓣狭窄的严重程度相关,并为不良结局提供独立的预后信息。然而,这种预测价值仅限于保守治疗的患者。因此,数据表明评估NT-proBNP可能对选择瓣膜置换的最佳时机具有额外价值。